Sign inJoin waitlistJoin the waitlist

AS

Adam Schoenfeld

Complex Therapeutics Section Head · New York Presbyterian Hospital

Credentials: · · · · · ·

History

New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
2020–2022
Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2017–2020
Internal Medicine
University of California-San Francisco
2014–2017
Univ of California, San Francisco Sch of Med
2010–2014

Research

Acquired Resistance to Immune Checkpoint Inhibitors
Review · Cancer Cell · 2020 · First of 2 authors · 795 citations
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
Journal of Clinical Oncology · 2023 · 381 citations
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
Annals of Oncology · 2019 · First of 10 authors · 351 citations

GR
Gregory Riely
26 papers
ML
Marc Ladanyi
26 papers
MA
Mark Awad
25 papers
AE
Arielle Elkrief
24 papers
Charles Rudin
23 papers
Biagio Ricciuti
22 papers · 22 as a resident
MK
Mark Kris
17 papers
MH
Matthew Hellmann
17 papers
HY
Helena Yu
16 papers
AD
Alexander Drilon
15 papers
Daniel Gomez
13 papers
JC
Jamie Chaft
13 papers

Clinical trials

A Study of Armored CAR T Cells in People With Cancer
Principal investigator · Recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2026–2029
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers
Principal investigator · Recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2026–2030
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2025–2026
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2015–2023